%0 Journal Article
%A Bovis, Francesca
%A Kalincik, Tomas
%A Lublin, Fred
%A Cutter, Gary
%A Malpas, Charles
%A Horakova, Dana
%A Havrdova, Eva Kubala
%A Trojano, Maria
%A Prat, Alexandre
%A Girard, Marc
%A Duquette, Pierre
%A Onofrj, Marco
%A Lugaresi, Alessandra
%A Izquierdo, Guillermo
%A Eichau, Sara
%A Patti, Francesco
%A Terzi, Murat
%A Grammond, Pierre
%A Bergamaschi, Roberto
%A Sola, Patrizia
%A Ferraro, Diana
%A Ozakbas, Serkan
%A Iuliano, Gerardo
%A Boz, Cavit
%A Hupperts, Raymond
%A Grand'Maison, Francois
%A Oreja-Guevara, Celia
%A van Pesch, Vincent
%A Cartechini, Elisabetta
%A Petersen, Thor
%A Altintas, Ayse
%A Soysal, Aysun
%A Ramo-Tello, Cristina
%A McCombe, Pamela
%A Turkoglu, Recai
%A Butzkueven, Helmut
%A Wolinsky, Jerry S
%A Solaro, Claudio
%A Sormani, Maria Pia
%T Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
%D 2020
%U https://hdl.handle.net/10668/27590
%X To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. The overall ARR ratio of GA to IFN-β-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-β-1a: in the trial, patients with the largest benefit from GA vs IFN-β-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSBase, with the corresponding ARR ratios of 0.58 (95% CI 0.46-0.72), 0.92 (95% CI 0.77-1.09,) and 1.29 (95% CI 0.97-1.71); heterogeneity p  We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-β-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.
%~